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In vitro platelet function tests are commonly applied in research and offer justification for using antiplatelet
therapy. However, studies assessing the ability of standardized platelet function tests to predict patients’
clinical response to aspirin or clopidogrel have generated contradictory results. At this time, there is no
standardized definition for resistance to antiplatelet therapy, and the appropriate treatment of patients who
are hyporesponsive to these agents is not known. Although such tests have a role in research, their place in
guiding therapy remains to be established, and prospective trials are urgently needed. The ideal platelet
function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable.
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Introduction
Tests of platelet function have been used in multiple
ways in both clinical and research settings.1,2 They
were first employed to screen patients for bleeding dis-
orders, and then to predict the risks of procedural
bleeding and thrombosis. More recently, with the advent
of more targeted prohemostatic and antiplatelet therapies,
platelet function tests have been used to assess medication
effectiveness, both during drug development and in clinical
situations.
For patients with cardiovascular disease (CVD), the major
applications of platelet function tests include the prediction
of clinical outcomes and the monitoring of antiplatelet
therapy. The key question relating to these issues is whether
standardized laboratory tests of platelet response to aspirin
(ASA) or clopidogrel therapy are predictive of the patient’s
clinical response to these agents. This article discusses the
currently available tests of platelet function, their advantages
and drawbacks, and their relationship to clinical outcomes of
antiplatelet therapy. Current guidelines for platelet function
testing and suggestions for additional research are also
discussed.
Current Platelet Function Tests
Table 1 details some of the characteristics of the most
commonly used platelet function tests.3,4 The historical
‘‘gold standard’’ is turbidometric platelet aggregometry,
which measures platelet coaggregation in platelet-rich
plasma (Figure 1).5 Samples are exposed to an agonist,
such as adenosine diphosphate (ADP) or arachidonic acid,
and the increase in light transmittance resulting from
platelet–platelet aggregation is measured. Its advantages
are that it can be used to monitor ASA, thienopyridines, and
platelet glycoprotein (GP) IIb/IIIa inhibitor therapy.3 Its
disadvantages include the large sample volumes required,
long processing times, and complex sample preparation.
Impedance aggregometry (Figure 2) is conceptually similar
to turbidometric platelet aggregometry, but, rather than
light transmission, it measures the increase in electrical
impedance across two precious metal wires that results
from platelet coaggregation in response to an agonist.5
It has the same disadvantages as turbidometric platelet
aggregometry, but it uses whole blood instead of platelet-
rich plasma.3
Other aggregation tests include the VerifyNow test
(Figure 3) (Acumetrics, San Diego, Calif., USA), a simple,
I-10 Clin. Cardiol. (Suppl. 1) 31, 3, I-10–I-16 (2008)
Published online in Wiley InterScience. (www.interscience.wiley.com)
DOI:10.1002/clc.20361  2008 Wiley Periodicals, Inc.
Received: November 20, 2007
Accepted: November 27, 2007








Historical ‘‘gold standard’’ Variable reproducibility; expensive;









VerifyNow Simple; rapid; POC; small sample
volume; no sample preparation;
whole-blood assay
No instrument adjustment Yesc Yesd Yese
Plateletworks Little sample preparation;
whole-blood assay
Not well studied Yesa Yesb Yes
Basis: Activation-dependent changes in platelet surface
Platelet surface P-selectin,
platelet surface activated GP
IIb/IIIa, leukocyte-platelet
aggregates






Platelet contribution to clot shear elasticity
Thromboelastogram POC; whole-blood assay; platelet clot
formation and clot lysis data
Limited studies Yesa Yesb Yes
Shear-induced platelet adhesion
Impact cone and plate(let)
analyzer
Simple; rapid; POC; small sample
volume; high shear; whole-blood
assay
Not widely available Yesa Yesb NR
Cessation of blood flow by platelet plug (for PFA, at high shear)
PFA-100 Simple; rapid; small sample volume;
no preparation; whole-blood assay










Activation-dependent release from platelets
Serum thromboxane B2 COX-1–dependent Indirect; not platelet-specific Yes No No
Urinary 11-dehydro-
thromboxane B2
COX-1–dependent Indirect; not platelet-specific;
depends on renal function
Yes No No
Adapted with permission from Michelson AD, et al.4 Abbreviations: ASA = aspirin; COX = cyclooxygenase; GP = glycoprotein; Hct = hematocrit; NR =
not recommended; PFA = platelet function analyzer; POC = point of care; VASP = vasodilator-stimulated phosphoprotein; vWF = von Willebrand factor;
aWith arachidonic acid; bWith ADP; cWith ASA cartridge; dWith P2Y12 cartridge; eWith TRAP cartridge.
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rapid, point-of-care method that has several other advan-
tages: required sample volumes are small, it uses whole
blood, and no pipetting is required.5 VerifyNow has been
used to monitor the pharmacodynamic effects of the 3 main
classes of antiplatelet therapies—ASA, thienopyridines, and
GP IIb/IIIa inhibitors.
Other methods assess activation-dependent changes on
the platelet surface. These tests include measurement of
levels of platelet surface P-selectin, activated GP IIb/IIIa, and
leukocyte–platelet aggregation. Their advantages include
the small sample volumes required and the use of whole
blood; disadvantages include complex sample preparation,
the requirement for flow cytometry and experienced
operators, and lack of commercial availability. They have
been used to monitor the various classes of antiplatelet
therapies.
The thromboelastogram (TEG) Platelet Mapping System
(Figure 4) measures platelet contribution to clot strength.5
It is a point-of-care method that uses whole blood to assess
platelet clot formation and clot-lysis data. It is able to monitor
all 3 classes of antiplatelet therapies. However, it requires
pipetting and has undergone only limited study. The Impact
cone and plate(let) analyzer is a simple, rapid, point-of-
care method that assesses shear-induced platelet adhesion.6
It uses whole blood, requires low-sample volumes, and
needs no sample preparation. The drawbacks include the
need for pipetting and lack of widespread availability. It is
not recommended for monitoring of GP IIb/IIIa inhibitor
therapy.
The Platelet Function Analyzer (PFA)-100 measures
in vitro the cessation of high-shear blood flow by the
platelet plug. It is a simple, rapid, point-of-care, whole blood
method that requires low sample volumes and no sample
preparation. Its disadvantages are that it is dependent on
von Willebrand factor (vWF) and hematocrit levels and that
it requires pipetting. It is not recommended for monitoring
of thienopyridines.6
Vasodilator-stimulated phosphoprotein (VASP) phospho-
rylation measures activation-dependent platelet signaling.
Its advantages include small required sample volumes, the
use of whole blood, stability (allowing samples to be shipped
to a remote laboratory), and dependency on the P2Y12 recep-
tor, the site of action for thienopyridines. Its disadvantages
are that it requires complex sample preparation, flow cytom-
etry, and experienced technicians, and cannot be used to
monitor ASA or GP IIb/IIIa inhibitor treatment.6
The serum thromboxane B2 level reflects its activation-
dependent release from platelets. Its chief advantage is that
it is dependent on cyclooxygenase (COX)-1, the specific
enzyme inhibited by ASA. However, thromboxane B2 levels
may be influenced by prostaglandins produced by leukocyte-
derived COX-2. Therefore, thromboxane B2 is not entirely
Figure 1: Turbidometric platelet aggregometer. It measures the decrease
in light transmittance that results from platelet coaggregation in
platelet-rich plasma, when samples are exposed to an agonist such as
ADP. Reproduced with permission from Harrison P et al.5
COX-1 or platelet specific. This indirect measure is not
completely platelet-specific, however. These characteristics
also apply to measurements of the ratio of the stable urinary
metabolite of thromboxane B2, 11-dehydro-thromboxane B2
(UDTB) to creatinine. These tests cannot be used to monitor
thienopyridines or GP IIb/IIIa inhibitor therapy.
The Relationship between Results of In Vitro Platelet Function
Tests and Clinical Response to Antiplatelet Therapy
When reviewing studies that have reported a link between
laboratory measures of platelet function and outcomes of
antiplatelet therapy in patients with CVD, it is important
to keep several cautions in mind. First, these studies have
generally included small numbers of patients (resulting in
relatively small numbers of events) and have been con-
ducted at single centers, precluding definitive conclusions.
There is an absence of serial measurements. The known
bias toward publication of ‘‘positive’’ studies must also be
considered. However, the concordance in reports should
also be recognized. It may also be difficult to assess the
relationship between in vitro platelet reactivity and clinical
outcomes because of inter- and intrapatient variability in
platelet responses to agonists such as ADP.7 Patient non-
compliance with study medication is also an important
practical issue because a noncompliant patient’s platelets
will appear not to respond well to the putative ingestion of
the antiplatelet agent.
Aspirin: Eikelboom and colleagues studied whether
hyporesponse to ASA treatment was related to the risk of
cardiovascular events, in a substudy of the Heart Outcomes
Prevention Evaluation (HOPE) secondary prevention trial.8
Baseline UDTB levels were compared among 488 patients
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Figure 2: Impedance platelet aggregometer. It measures the increase in
electrical impedance across two precious metal wires that results from
platelet coaggregation in whole blood, when samples are exposed to an
agonist such as ADP. Reproduced with permission from Harrison P et al.5
receiving ASA who had myocardial infarction (MI), stroke,
or cardiovascular death over 5 years of follow-up and 488 sex-
and age-matched control patients taking ASA who had no
such event. The adjusted odds ratio (OR) for the composite
endpoint was 1.8 times higher for patients in the upper
quartile of UDTB level compared with patients in the lowest
UDTB quartile (p = 0.009) (Figure 5). Similar patterns were
shown for the component events of MI (adjusted OR,
2.0; p = 0.006) and cardiovascular death (adjusted OR, 3.5;
p<0.001), but not for stroke. Thus, elevated UDTB levels
appeared to identify patients whose platelets responded
suboptimally to ASA treatment in this study.
Gum and colleagues assessed the relationship between
hyporesponse to ASA treatment and the composite inci-
dence of death, MI, or stroke in 326 US patients with stable
CVD.9 Hyporesponse was defined as mean platelet aggre-
gation of  70% in response to 10µmol/L ADP agonism
and aggregation  20% with 0.5 mg/mL arachidonic acid
Figure 3: The VerifyNow platelet aggregometer. Reprinted with
permission from Harrison P et al.5
Figure 4: The Thromboelastogram (TEG) Platelet Mapping system.
Reproduced with permission from Harrison P et al.5
stimulation. In all, 5.2% of patients showed hyporesponse
to ASA. Of these patients, 24% reached the composite end-
point over a mean 1.8 years of follow-up versus only 10% of
patients with a ‘‘normal’’ response (p = 0.03). However, the
relationships between hyporesponse (whether a categorical
or continuous variable) and component event rates were not
statistically significant. Of note, these same investigators
had previously shown that hyporesponse as defined above
did not correlate well with hyporesponse as assessed by the
PFA-100 test (defined as having a normal collagen and/or
epinephrine closure time) in this population.10
Ohmori and colleagues assessed the relationship between
platelet hyporesponse to ASA therapy and clinical out-
comes in 136 patients with stable CVD.11 They assessed
platelet responses to collagen stimulation by both standard
light-transmittance aggregometry and by light-scattering
intensities with a PA-20 aggregation analyzer (reflecting
small, medium, or large aggregates). Patients in the upper
quartile of aggregation by light transmittance, or who had
large aggregates, had a significantly and independently
increased risk of MI, cerebrovascular infarction, or car-
diovascular death at 12 months (hazard ratio [HR], 7.76;
p = 0.008 for light transmittance aggregometry; HR, 7.98;
p = 0.007 for large aggregates).
Chen and colleagues examined the relationship between
serum markers of myonecrosis after nonurgent percuta-
neous coronary intervention (PCI) and hyporesponse to ASA
therapy among 151 patients pretreated with clopidogrel.12
Response to ASA was assessed by a commercially available,
point-of-care assay, the VerifyNow Ultegra Rapid Platelet
Function Assay-ASA (RPFA-ASA). Hyporesponse to ASA
was defined as an ASA reaction unit of  550 at baseline
(before clopidogrel treatment and PCI) blood sampling.
Myonecrosis was measured by creatine kinase-myocardial
band (CK-MB) and troponin I (TnI) elevations after PCI. In
all, 19.2% of the patients were hyporesponsive to ASA, and
significantly more of these patients were women. After clopi-
dogrel treatment and PCI, 51.7% of the ASA-hyporesponsive
patients showed elevated CK-MB levels compared with
24.6% of the ASA-responsive patients (p = 0.006); 65.5% and
38.5% of patients, respectively, showed elevations in TnI
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levels (p = 0.012). Hyporesponse to ASA was one of two
independent predictors of CK-MB elevation after PCI in
multivariable analysis (OR, 2.9; p = 0.015). Thus, despite
adequate pretreatment with clopidogrel, patients with a
lesser response to ASA treatment in this study remained at
increased risk of myonecrosis after PCI.
Clopidogrel: Matetzky and colleagues examined the
relationship between hyporesponse to clopidogrel treatment
and clinical outcomes in 60 consecutive patients with MI
undergoing primary PCI with stenting at one center.13 All
received clopidogrel, ASA, and eptifibatide. Controls were
10 consecutive patients undergoing primary PCI alone who
received no clopidogrel. Platelet aggregation was assessed
by cone and plate(let) analysis and aggregation responses
to 5µmol/L ADP and 10µmol/L epinephrine. Patients
were first grouped into quartiles by percent reduction in
ADP-induced aggregation from baseline to Day 6; values
ranged from 103% of the baseline value in the first quartile
(clopidogrel hyporesponse; n = 15) to 33% of the baseline
value in the fourth quartile (p<0.01 across groups). Similar
patterns were shown for epinephrine-induced aggregation
and the cone and plate(let) analysis. Patients in the
clopidogrel-hyporesponse group experienced 7 of the 8
major cardiac events that occurred during the 6-month
follow-up. In all, 40% of these patients had another ischemic
event, whereas 13% of patients in the fourth quartile had
major bleeding. Angiographic findings and infarct size

































Figure 5: Risk of myocardial infarction, stroke, or cardiovascular death by
quartile of urinary 11-dehydro-thromboxane B2 level among patients in a
substudy of the HOPE secondary prevention trial of ASA. Adapted with
permission from Eikelboom JW et al.8
recurrent events were older and had a higher Killip class
at presentation, and the analysis did not adjust for these
or other risk factors. The investigators did not report data
regarding a correlation between cone and plate(let) analysis
and clinical outcomes.
Gurbel and colleagues used VASP phosphorylation
to examine the relationship between platelet reactivity
to clopidogrel treatment and stent thrombosis.14 They
compared platelet reactivity to ADP and P2Y12 activity in
20 patients who developed subacute stent thrombosis after
clopidogrel therapy versus that of 100 age-matched controls.
Both measures were significantly increased in patients with
thrombosis, but there was substantial overlap in values
between groups. Of note, patients with <40% aggregation
had no stent thrombosis, representing a possible threshold
effect. Other investigators have reported a relationship
between incomplete P2Y12 receptor blockade by clopidogrel
as assessed by VASP phosphorylation and stent thrombosis
and greater shear-induced platelet aggregation in patients
with stent thrombosis compared with thrombosis-free
patients or volunteers.15,16
Finally, Wenaweser and colleagues have studied the
relative associations between ASA and clopidogrel hypo-
response and subacute stent thrombosis.17 They compared
23 patients with previous stent thrombosis (median, 7 days
after implantation) at 1 center with 50 patients who had
undergone stenting without developing thrombosis and with
9 healthy volunteers. Platelet aggregation in response to 5
and 20µmol/L ADP was assessed via optical aggregometry
during 1 month of ASA monotherapy and during a second
month of combined ASA and clopidogrel treatment (after
a 300 mg loading dose of clopidogrel). Maximal platelet
aggregation was significantly higher in patients with stent
thrombosis than in controls or volunteers. Hyporesponse to
ASA, defined as >20% aggregation in response to 0.5 mg/mL
arachidonic acid, was more common in patients with stent
thrombosis (48%) than in control patients (32%, p = NS)
or volunteers (0%, p = 0.01). Hyporesponse to clopidogrel,
defined as a less than 10% relative change in aggregation,
did not differ significantly among groups (4% of patients
with stent thrombosis, 6% of control patients, and 11% of
the volunteers, respectively, all p = NS). Hyporesponse to
both ASA and clopidogrel, however, was more common in
patients with stent thrombosis (52%) than in controls (38%,
p = NS) or volunteers (11%, p<0.05). The investigators
concluded that hyporesponse to ASA, but not to clopidogrel
may be associated with a risk of thrombosis after stenting.
Current Role of Platelet Reactivity Testing
According to the most recent consensus statement on
the use of antiplatelet agents and position paper on ASA
‘‘resistance’’ from the International Society on Thrombosis
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and Haemostasis, it is currently not recommended to test
patients for ASA or clopidogrel resistance outside of clinical
trials or to change therapy based on such testing.18,19 There
are two main reasons for these recommendations. First, a
clinically meaningful, standardized definition of resistance
based on data linking therapy-dependent laboratory tests
to clinical outcomes has yet to be developed.19 Second,
the correct treatment of patients whose platelets are
hyporesponsive to antiplatelet agents is unknown, given that
no study has assessed clinical effectiveness after altering
therapy based on laboratory findings of hyporesponse.19
The American College of Cardiology/American Heart
Association/Society for Cardiovascular Angiography and
Interventions guidelines recommend daily ASA therapy
after PCI for patients without ASA ‘‘resistance,’’ but no
definition of resistance is offered.20 For clopidogrel, the
guidelines state that ‘‘ . . .in patients in whom stent
thrombosis may be catastrophic or lethal. . . platelet
aggregation studies may be considered and the dose of
clopidogrel increased to 150 mg per day if less than 50%
inhibition of platelet aggregation is demonstrated.’’ This
is a Class IIb, level C recommendation, indicating that
there is disagreement over whether the intervention is
considered beneficial, and that the recommendation reflects
only consensus opinion, not data from randomized clinical
trials. Finally, the method to assess platelet inhibition is not
described.
Adequately powered clinical trials are urgently needed to
address 3 pivotal questions. First, which simple, inexpen-
sive, and rapid test of platelet function (or combination of
tests) best predicts clinical outcomes of antiplatelet therapy
for specific patient subgroups? Second, are individual out-
comes affected when treatment is changed in response to
the test(s) results? The goal here would be development of
thresholds for test results, similar to the practice of adjust-
ing warfarin therapy by international normalized ratio (INR)
results.21,22 Third, what is the benefit of dose titration or
supplementary treatment with an agent having a different
mechanism of action in patients with known hyporesponse
to antiplatelet agents? For example, if a patient with CVD suf-
fers an event while already taking ASA, is it more effective to
increase the dose of ASA, add a thienopyridine for additional
secondary prevention, or both, rather than to simply sub-
stitute the thienopyridine for ASA? Recent reports of early
and late thrombosis of drug-eluting stents after interruption
of antiplatelet therapy have raised concern about stopping
antiplatelet therapy altogether after an acute cardiovascular
event, but there are few data to guide clinicians in this
regard.23–25 Clinical trials can provide the robust evidence
needed to answer these questions, which are so important
to clinicians.
Conclusions
Tests of platelet function in vitro are widely used in research
and provide a mechanistic rationale for antiplatelet therapy.
Correlating the results of such tests with clinical outcomes
and using the results to guide therapy, however, remain
challenging goals. The ideal test of platelet function for use
in clinical practice would be rapid, easy-to-use, inexpensive,
and would be a reliable indicator of the clinical response to
the specific antiplatelet therapy or combination of therapies.
Prospective clinical trials are now needed.
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